The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking-Reference-Cited by-同舟云学术

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

Published:2016-06-17 Issue:3 Volume:197 Page:807-813
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Overdijk Marije B.,Jansen J. H. Marco,Nederend Maaike,Lammerts van Bueren Jeroen J.,Groen Richard W. J.,Parren Paul W. H. I.^ORCID,Leusen Jeanette H. W.,Boross Peter

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference48 articles.

1. Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma

2. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

3. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

4. Usmani S. Z. Weiss B. M. Plesner T. Bahlis N. J. Belch A. Lonial S. Lokhorst H. M. Voorhees P. M. Richardson P. G. Chari A. . 2016. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. DOI: 10.1182/blood-2016-03-705210.

5. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09

2. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study;Annals of Hematology;2024-09-04

3. Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma;Blood Neoplasia;2024-09

4. From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy;Recent Patents on Anti-Cancer Drug Discovery;2024-08

5. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial;The Lancet Oncology;2024-08